Bimatoprost Versus Travoprost at Cairo University

Cairo University (CU)

Status: Completed

Conditions: Glaucoma; Ocular Hypertension

Study type: Observational

Funder types: Other

Identifiers

NCT01092273

Prostaglandins-Cairo-1A

Details and patient eligibility

About

Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months.

These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Sex: All

Ages: 20 to 72 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Glaucoma and Ocular Hypertension

Exclusion criteria

• Any ocular disease or medication that may raise the intraocular pressure.

Trial design

0 participants in 1 patient group

Bimatoprost versus Travoprost